PRIMA clinical trial: Universal Radical Cure of P. vivax malaria

20 Nov 2019
Chief investigator: Dr Kamala Ley-Thriemer; Investigators Dr Benedikt Ley – Menzies School of Health Research Professor Ric Price -Menzies School of Health Research Professor Asrat Hailu – Addis Abeba University, Ethiopia Dr Tamiru Degaga -ArbaMinch University, Ethiopia Dr Shafiul Alam –icddr,b, Bangladesh Dr Wasif Ali Khan – icddr,b, Bangladesh Professor Inge Sutanto- Faculty of Medicine Universitas, Indonesia Professor Kevin Baird- Eijkman-Oxford Clinical Research Unit (EOCRU), Indonesia


Study title:

Reducing the risk of P. vivax after falciparum infections in co-endemic areas - a randomized controlled trial (PRIMA).

Study purpose:

To compare the safety and efficacy of a high dose primaquine treatment in G6PD normal patients with P. falciparum to reduce the risk of subsequent P. vivax episodes to current standard practice for P. falciparum

Objectives:

Primary

  • To assess the safety and efficacy of a 7-day course of high dose primaquine treatment regimen in preventing recurrent symptomatic P. vivax parasitaemia in G6PD normal patients following uncomplicated P. falciparum malaria.

Secondary

  • To assess the efficacy of a 7-day course of high dose primaquine treatment regimen in preventing recurrent symptomatic and asymptomatic P. vivax and parasitaemia
  • To assess the relationship between Hb and G6PD activity over time

For more information visit the clinical trials website.